Outcome	No. of studies	No. of participants	Statistical method	Effect size	Vaccine efficacy (95% CI)
Confirmed SARS‐CoV‐2 infection after complete vaccination	1	6289	N/A	N/A	68.80% (46.70% to 82.50%)
Confirmed symptomatic COVID‐19 after complete vaccination	1	16,973	N/A	N/A	77.80% (65.20% to 86.40%)
Severe or critical COVID‐19 after complete vaccination	1	16,976	N/A	N/A	93.40% (57.10% to 99.80%)
All‐cause mortality	1	25,753	Risk Ratio (M‐H, Random, 95% CI)	0.50 (0.17 to 1.46)	N/A
Serious adverse events	1	25,753	Risk Ratio (M‐H, Random, 95% CI)	0.65 (0.43 to 0.97)	N/A
Systemic reactogenicity events	2	25,925	Risk Ratio (M‐H, Random, 95% CI)	1.34 (1.15 to 1.58)	N/A
Any adverse event	1	25,753	Risk Ratio (M‐H, Random, 95% CI)	1.00 (0.94 to 1.07)	N/A
Local reactogenicity events	2	25,750	Risk Ratio (M‐H, Random, 95% CI)	1.08 (0.95 to 1.24)	N/A